Home LiteratureArticle Details
PMID: 20181720 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't

Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.

Journal of virology ·Vol. 84 ·No. 9 ·2010-05-00 ·Pages 4611-8

Schwartz JA, Buonocore L, Suguitan AL, Silaghi A, Kobasa D, Kobinger G, Feldmann H, Subbarao K, Rose JK

Abstract

The emergence in 1997 and continuance today of a highly lethal H5N1 avian influenza virus (AIV) causing human disease has raised concern about an impending pandemic and the need for a vaccine to prepare for such an occurrence. We previously generated an efficacious vesicular stomatitis virus (VSV)-based AIV vaccine expressing H5 hemagglutinin (HA) from the fifth genomic position of VSV (J. A. Schwartz et al., Virology 366:166-173, 2007). Here we have generated and characterized VSV-based vaccines that express the A/Hong Kong/156/1997 (clade 0) H5 HA from the first position of the VSV genome. These vectors induce broadly cross-neutralizing antibodies against homologous and heterologous H5N1 viruses of different clades in mice. The vaccines provide complete protection against morbidity and mortality after heterologous challenge with clade 0 and clade 1 strains in animals even 1 year after vaccination. Postchallenge pulmonary virus loads show that these vectors provide sterilizing immunity. Therefore, VSV-based AIV vaccines are potent, broadly cross-protective pandemic vaccine candidates.

MeSH Terms
Animals Antibodies, Neutralizing/blood Antibodies, Viral/blood Body Weight Cross Protection Female Genetic Vectors Hemagglutinin Glycoproteins, Influenza Virus/genetics,immunology Influenza A Virus, H5N1 Subtype/immunology Influenza Vaccines/genetics,immunology Lung/virology Mice Mice, Inbred BALB C Orthomyxoviridae Infections/prevention & control,virology Survival Analysis Time Factors Vesiculovirus/genetics Viral Plaque Assay
Chemicals
Antibodies, Neutralizing Antibodies, Viral Hemagglutinin Glycoproteins, Influenza Virus Influenza Vaccines hemagglutinin, avian influenza A virus
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Schwartz Jennifer A
Department of Pathology, Yale University School of Medicine, 310 Cedar St., LH 315, New Haven, CT 06520, USA.
Buonocore Linda
Suguitan Amorsolo L
Silaghi Alex
Kobasa Darwyn
Kobinger Gary
Feldmann Heinz
Subbarao Kanta
Rose John K
References (39)
39 references, click to expand
  1. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.
    J Virol. 2008 Jan;82(1):207-19 PMID: 17942549
  2. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
    PLoS One. 2008 Jan 02;3(1):e1401 PMID: 18167560
  3. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins.
    J Virol. 2002 Aug;76(15):7506-17 PMID: 12097563
  4. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.
    PLoS Med. 2006 Sep;3(9):e360 PMID: 16968127
  5. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.
    Virology. 2005 Sep 30;340(2):174-82 PMID: 16043204
  6. Emerging respiratory viruses: challenges and vaccine strategies.
    Clin Microbiol Rev. 2006 Oct;19(4):614-36 PMID: 17041137
  7. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture.
    N Engl J Med. 2008 Jun 12;358(24):2573-84 PMID: 18550874
  8. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1.
    J Virol. 2000 Dec;74(23):10903-10 PMID: 11069984
  9. A vesicular stomatitis virus recombinant expressing granulocyte-macrophage colony-stimulating factor induces enhanced T-cell responses and is highly attenuated for replication in animals.
    J Virol. 2005 Dec;79(24):15043-53 PMID: 16306575
  10. Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.
    PLoS Pathog. 2008 Nov;4(11):e1000225 PMID: 19043556
  11. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.
    N Engl J Med. 2006 Mar 30;354(13):1343-51 PMID: 16571878
  12. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.
    Vaccine. 2008 Dec 9;26(52):6894-900 PMID: 18930776
  13. Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge.
    J Virol. 1998 Jun;72(6):4704-11 PMID: 9573234
  14. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls.
    J Virol. 2005 Mar;79(5):2814-22 PMID: 15709000
  15. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
    Proc Natl Acad Sci U S A. 1986 Nov;83(21):8122-6 PMID: 3095828
  16. Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.
    Vaccine. 2009 Nov 16;27(49):6918-25 PMID: 19761837
  17. An avian live attenuated master backbone for potential use in epidemic and pandemic influenza vaccines.
    J Gen Virol. 2008 Nov;89(Pt 11):2682-2690 PMID: 18931063
  18. Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.
    Virology. 2007 Sep 15;366(1):166-73 PMID: 17524441
  19. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses.
    Vaccine. 2008 Sep 12;26 Suppl 4:D31-4 PMID: 19230156
  20. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    J Infect Dis. 2006 Jul 15;194(2):159-67 PMID: 16779721
  21. The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.
    Vaccine. 2006 Apr 24;24(17):3669-76 PMID: 16378663
  22. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription.
    Cell. 1981 Feb;23(2):477-84 PMID: 6258804
  23. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice.
    J Virol. 1999 Mar;73(3):2094-8 PMID: 9971791
  24. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus.
    BioDrugs. 2008;22(5):279-92 PMID: 18778110
  25. Evolution of H5N1 avian influenza viruses in Asia.
    Emerg Infect Dis. 2005 Oct;11(10):1515-21 PMID: 16318689
  26. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
    PLoS One. 2009;4(2):e4384 PMID: 19197383
  27. Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection.
    Cell. 1997 Sep 5;90(5):849-57 PMID: 9298897
  28. Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates.
    J Virol. 2008 Jun;82(11):5664-8 PMID: 18385248
  29. Attenuated vesicular stomatitis viruses as vaccine vectors.
    J Virol. 1999 May;73(5):3723-32 PMID: 10196265
  30. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice.
    Lancet. 2006 Feb 11;367(9509):475-81 PMID: 16473124
  31. SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector.
    Virology. 2008 Jun 20;376(1):165-72 PMID: 18396306
  32. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    J Virol. 2001 Nov;75(22):11079-87 PMID: 11602747
  33. Strategies for developing vaccines against H5N1 influenza A viruses.
    Trends Mol Med. 2006 Nov;12(11):506-14 PMID: 17011235
  34. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control.
    Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2845-50 PMID: 16473931
  35. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans.
    J Virol. 1999 Jul;73(7):5903-11 PMID: 10364342
  36. Intramuscular immunization with a vesicular stomatitis virus recombinant expressing the influenza hemagglutinin provides post-exposure protection against lethal influenza challenge.
    Vaccine. 2009 Dec 10;28(1):79-89 PMID: 19819211
  37. A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses.
    J Infect Dis. 2008 Apr 15;197(8):1185-8 PMID: 18462165
  38. Recombinant vesicular stomatitis viruses from DNA.
    Proc Natl Acad Sci U S A. 1995 May 9;92(10):4477-81 PMID: 7753828
  39. High-level primary CD8(+) T-cell response to human immunodeficiency virus type 1 gag and env generated by vaccination with recombinant vesicular stomatitis viruses.
    J Virol. 2002 Mar;76(6):2730-8 PMID: 11861840
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
DOI
10.1128/JVI.02637-09
Published
2010-05-00
Epub
2010-00-24
Pages
4611-8
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2863739
Subset
IM
Grants
CIHR · 166339 · Canada
NIAID NIH HHS · R01 AI080781 · United States
NIAID NIH HHS · U54 AI057158 · United States
Intramural NIH HHS · United States
CIHR · 310641 · Canada
External Links
PubMed source DOI: 10.1128/JVI.02637-09 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2